DxTerity Diagnostics Revenue and Competitors

Compton, CA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • DxTerity Diagnostics's estimated annual revenue is currently $8.8M per year.(i)
  • DxTerity Diagnostics's estimated revenue per employee is $215,488

Employee Data

  • DxTerity Diagnostics has 41 Employees.(i)
  • DxTerity Diagnostics grew their employee count by -20% last year.

DxTerity Diagnostics's People

NameTitleEmail/Phone
1
CFO and SVP Business Development, Co-FounderReveal Email/Phone
2
VP Product DevelopmentReveal Email/Phone
3
Chemical Hygiene OfficerReveal Email/Phone
4
Founder and CEOReveal Email/Phone
5
Research AssociateReveal Email/Phone
6
Genomic Client ServicesReveal Email/Phone
7
Administrative AssistantReveal Email/Phone
8
Scientist, Product DevelopmentReveal Email/Phone
9
Molecular Laboratory TechnicianReveal Email/Phone
10
Laboratory Operations TechnicianReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M50%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M4-50%N/AN/A
#6
$0.7M80%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1731%N/AN/A
Add Company

What Is DxTerity Diagnostics?

DxTerity is a privately owned biotechnology company located in Southern California. The company’s focus is to utilize the patented NEAT™ platform to provide a pathway to incorporate genetic testing—even complex gene signatures—into routine medical care.

keywords:N/A

N/A

Total Funding

41

Number of Employees

$8.8M

Revenue (est)

-20%

Employee Growth %

N/A

Valuation

N/A

Accelerator

DxTerity Diagnostics News

2022-03-22 - LA Is Fertile Ground for Covid Testing Companies

Diagnostic roots · What's after Covid? · DxTerity Diagnostics Inc. · BiologyWorks Inc. · Applied BioCode Inc. · Curative LABS Inc. · Sameday...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M438%N/A
#2
$5.9M4326%N/A
#3
$11.5M4612%N/A
#4
$9.2M4817%N/A
#5
$35M492%N/A